Clinical Use: P1NP reflects osteoblast activity so any disease increasing the activity of osteoblasts or activation frequency of the bone forming unit will result in elevated P1NP concentrations. Low P1NP may indicate adynamic bone. P1NP is useful in monitoring response to anti-resorption therapy.

The positive least significant change (LSC) was determined to be 37.8%, meaning that an individual should display a ≥ 37.8% increase of P1NP concentrations when monitoring disease, to have a <5 % chance (p < 0.05) of the increase being the result of random variation in marker concentration. The negative LSC was determined to be -27.4%, meaning that an individual should display a ≤ 27.4% decrease of P1NP concentrations when receiving anti-resorptive therapy, to have a <5 % chance (p < 0.05) of the decrease being the result of random variation in marker concentration.

Patient preparation: None. P1NP shows minimal circadian rhythm or seasonal variation and food intake or diet show no detectable influence on serum levels. A baseline pre-treatment measurement is required if assessing response to antiresorption therapy.

Sample requirements: Lithium heparin plasma, EDTA plasma or serum. Send by first class post avoiding weekends. Minimum sample requirement - 0.5 ml serum/plasma.

Reference ranges

Pre menopausal Females	30 - 78	µg/l
Post Menopausal Females	26 -110	µg/l
Males	20 -76	µg/l

Additional information on P1NP and its clinical use can be found here: P1NP.

ICE requesting info:	ICE panel name	ICE page name	Column	Comment\Advice
	Chem / Haem	Bone Metab	2

Back

Laboratory Services Home Page